Form EFFECT Day One Biopharmaceutica
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Day One Biopharmaceuticals (DAWN) IPO Opens 56% Higher
May 27, 2021 11:39 AM EDTToday's IPO for Day One Biopharmaceuticals (NASDAQ: DAWN) opened for trading at $25 after pricing 10,000,000 shares of its common stock at a public offering price of $16.00 per share.
J.P. Morgan, Cowen and Piper Sandler are acting as joint bookrunning managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
Day One is... More
